The University of Louisville has received a total of $3.6 million in funding from the U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) for research into potentially harmful chemicals found in electronic cigarettes.
Researchers will be creating electronic cigarette products with various flavors to determine potential short-term and long-term health effects.
Based on our current understanding, there is toxicity present in some flavors," said Alex Carll, co-leader of the project and associate professor at the University of Louisville.
Researchers aim to identify which chemicals have adverse effects on the body, particularly the heart, due to the plethora of flavors available on the market.
To determine the risks associated with various flavor combinations, researchers will test them on mice and monitor their heart rates, simulating the way people inhale electronic cigarettes.
Subsequently, researchers will test individual chemicals on myocardial cells.
Researcher will analyze data to determine the short-term and long-term health effects of certain chemicals over time.
Carll stated, "As a scientist, I may not be able to determine what is right or wrong, but I can at least inform the public about the toxicity of certain seasoning chemicals.
According to researchers involved, funding for this study will continue until 2027 and they have reported preliminary results.
Source: WLKY (Note: The original text is already in English, so there is no need to translate it.)
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
